Complete Filing Data
Nuvectis Pharma, Inc. reported Stockholders Equity of $18.41 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Nuvectis Pharma, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| Operating Income Loss | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Net Income Loss Available To Common Stockholders Basic | -$28.9M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| General And Administrative Expense | $9.4M | $6.9M | $7.5M | $6.0M | $3.3M |
| Research And Development Expense | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$7.5M | -$6.3M | -$5.3M | -$4.2M | -$4.4M | -$4.2M | -$5.9M | -$5.7M | -$4.0M | -$5.9M | -$3.6M | -$2.9M | -$4.7M | -$5.9M | -$23.0K |
| Operating Income Loss | -$7.8M | -$6.6M | -$5.6M | -$4.4M | -$4.6M | -$4.4M | -$6.2M | -$5.8M | -$4.1M | -$5.9M | -$3.6M | -$2.9M | -$4.7M | -$5.9M | -$23.0K |
| Net Income Loss Available To Common Stockholders Basic | -$9.9M | -$6.3M | -$5.3M | -$4.2M | -$4.4M | -$4.2M | -$5.9M | -$5.7M | -$4.0M | -$5.9M | -$3.6M | -$2.9M | -$4.7M | -$5.9M | -$23.0K |
| General And Administrative Expense | $2.0M | $3.0M | $1.9M | $1.5M | $1.7M | $1.7M | $1.7M | $1.5M | $1.7M | $1.4M | $1.1M | $1.1M | $512.0K | $1.7M | $23.0K |
| Research And Development Expense | $5.8M | $3.6M | $3.7M | $2.8M | $2.9M | $2.7M | $4.5M | $4.3M | $2.4M | $4.5M | $2.5M | $1.8M | $4.2M | $4.2M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M | -$10.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M | |
| Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium | $6.0M | $4.9M | $4.7M | $1.7M | ||
| Retained Earnings Accumulated Deficit | -$99.7M | -$73.2M | -$54.2M | -$32.0M | -$12.9M | |
| Other Assets Current | $75.0K | $74.0K | $59.0K | $412.0K | $91.0K | |
| Liabilities Current | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M | |
| Liabilities And Stockholders Equity | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M | |
| Liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M | |
| Employee Related Liabilities Current | $6.9M | $5.6M | $3.8M | $2.4M | $142.0K | |
| Assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M | |
| Accrued Liabilities Current | $115.0K | $840.0K | $415.0K | $445.0K | $395.0K | |
| Accounts Payable Current | $6.3M | $2.5M | $2.8M | $2.9M | $1.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $13.1M | -$593.0K | -$867.0K | $14.3M | $5.7M | |
| Accrued Offering Costs | $450.0K | $824.0K | ||||
| Unpaid Deferred Offering Costs | $450.0K | $824.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $24.0M | $16.9M | $21.0M | $11.0M | $12.5M | $14.0M | $16.7M | $20.3M | $12.3M | $20.4M | $11.5M | $14.6M | -$8.9M | -$4.4M | -$33.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $35.4M | $26.8M | $29.9M | $17.2M | $18.1M | $19.5M | $22.1M | $24.6M | $15.5M | $23.6M | $13.6M | $16.7M | $6.8M | $7.2M | |
| Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium | $1.5M | $1.7M | $1.4M | $1.2M | $1.3M | $1.3M | $1.1M | $950.0K | $1.4M | $559.0K | $510.0K | $156.0K | |||
| Retained Earnings Accumulated Deficit | -$92.4M | -$84.9M | -$78.6M | -$67.0M | -$62.8M | -$58.4M | -$47.6M | -$41.7M | -$36.0M | -$25.3M | -$19.4M | -$15.8M | |||
| Other Assets Current | $145.0K | $214.0K | $284.0K | $138.0K | $182.0K | $250.0K | $203.0K | $341.0K | $740.0K | $1.2M | $666.0K | $925.0K | |||
| Liabilities Current | $11.6M | $10.1M | $9.2M | $6.3M | $5.8M | $5.7M | $5.6M | $4.6M | $3.9M | $4.5M | $2.7M | $3.1M | |||
| Liabilities And Stockholders Equity | $35.6M | $27.0M | $30.1M | $17.3M | $18.3M | $19.7M | $22.3M | $24.9M | $16.2M | $24.9M | $14.2M | $17.6M | |||
| Liabilities | $11.6M | $10.1M | $9.2M | $6.3M | $5.8M | $5.7M | $5.6M | $4.6M | $3.9M | $4.5M | $2.7M | $3.1M | |||
| Employee Related Liabilities Current | $5.0M | $5.1M | $5.0M | $3.8M | $3.6M | $3.4M | $1.9M | $1.8M | $1.7M | $863.0K | $173.0K | $92.0K | |||
| Assets | $35.6M | $27.0M | $30.1M | $17.3M | $18.3M | $19.7M | $22.3M | $24.9M | $16.2M | $24.9M | $14.2M | $17.6M | |||
| Accrued Liabilities Current | $65.0K | $2.0K | $865.0K | $282.0K | $310.0K | $486.0K | $158.0K | $571.0K | $156.0K | $738.0K | $790.0K | $697.0K | |||
| Accounts Payable Current | $6.4M | $5.0M | $3.0M | $2.3M | $1.8M | $1.8M | $3.5M | $1.8M | $2.1M | $2.3M | $1.4M | $1.3M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $11.3M | $338.0K | -$4.5M | $11.0M | |||||||||||
| Accrued Offering Costs | $75.0K | $75.0K | $300.0K | $399.0K | $640.0K | $341.0K | $921.0K | ||||||||
| Unpaid Deferred Offering Costs | $97.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $6.0M | $4.9M | $4.7M | $1.7M | $1.9M |
| Net Cash Provided By Used In Operating Activities | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Net Cash Provided By Used In Financing Activities | $29.1M | $11.7M | $15.1M | $27.8M | $15.2M |
| Increase Decrease In Other Current Assets | $1.0K | $15.0K | -$353.0K | $321.0K | $91.0K |
| Increase Decrease In Accrued Liabilities | -$725.0K | $425.0K | -$30.0K | $338.0K | |
| Increase Decrease In Accrued Compensation And Benefits | $1.4M | $1.8M | $1.4M | $2.0M | |
| Increase Decrease In Accounts Payable | $3.8M | -$273.0K | -$139.0K | $1.9M | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $4.1M | $1.6M | |||
| Payments Of Stock Issuance Costs | $382.0K | $174.0K | |||
| Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation | $1.7M | $1.9M | |||
| Proceeds From Issuance Of Common Stock | $12.0M | $5.3M | |||
| Proceeds From Warrant Exercises | $11.2M | ||||
| Proceeds From Issuance Initial Public Offering | $16.0M | ||||
| Payments Of Stock Issuance Costs Related To Initial Public Offering | $341.0K | ||||
| Payments Of Stock Issuance Costs Related To Private Placement | $508.0K | ||||
| Proceeds From Issuance Of Private Placement | $15.9M | ||||
| Payments Of Issuance Costs For Warrant Exercise And Preferred Investment Option | $371.0K | ||||
| Net Cash Provided By Used In Investing Activities | $0.00 | $0.00 | $0.00 | ||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $15.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $1.4M | $1.3M | $1.4M | $156.0K | |||||
| Net Cash Provided By Used In Operating Activities | -$4.2M | -$4.4M | -$4.8M | -$3.1M | |||||
| Net Cash Provided By Used In Financing Activities | $15.5M | $4.7M | $252.0K | $14.0M | |||||
| Increase Decrease In Other Current Assets | $210.0K | $191.0K | $328.0K | $831.0K | |||||
| Increase Decrease In Accrued Liabilities | $25.0K | $71.0K | -$289.0K | ||||||
| Increase Decrease In Accrued Compensation And Benefits | -$519.0K | -$351.0K | -$699.0K | ||||||
| Increase Decrease In Accounts Payable | $494.0K | -$1.0M | -$814.0K | ||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$1.8M | $542.0K | $23.0K | ||||||
| Payments Of Stock Issuance Costs | $153.0K | $2.0M | |||||||
| Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation | $1.4M | $559.0K | $510.0K | $156.0K | $136.0K | $1.6M | |||
| Proceeds From Issuance Of Common Stock | $4.8M | ||||||||
| Proceeds From Warrant Exercises | $702.0K | ||||||||
| Proceeds From Issuance Initial Public Offering | $16.0M | ||||||||
| Payments Of Stock Issuance Costs Related To Initial Public Offering | $341.0K | ||||||||
| Payments Of Stock Issuance Costs Related To Private Placement | $109.0K | ||||||||
| Proceeds From Issuance Of Private Placement | |||||||||
| Payments Of Issuance Costs For Warrant Exercise And Preferred Investment Option | |||||||||
| Net Cash Provided By Used In Investing Activities | $0.00 | $0.00 | |||||||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 21.8M | 17.1M | 15.6M | 12.7M | 4.3M | |
| Weighted Average Number Of Diluted Shares Outstanding | 21.8M | 17.1M | 15.6M | 12.7M | 4.3M | |
| Earnings Per Share Diluted | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 | |
| Earnings Per Share Basic | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 | |
| Common Stock Shares Authorized | 60.0M | 60.0M | 60.0M | 60.0M | 12.9M | 3.9M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Issued | 25.7M | 19.5M | 17.4M | 15.2M | 4.5M | |
| Common Stock Shares Outstanding | 25.7M | 19.5M | 17.4M | 15.2M | 4.5M | |
| Temporary Equity Shares Authorized | ||||||
| Temporary Equity Shares Outstanding | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 22.7M | 21.4M | 19.9M | 17.2M | 16.9M | 16.6M | 16.1M | 15.2M | 14.7M | 14.1M | 12.7M | 9.2M | 4.5M | 4.2M | 3.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 22.7M | 21.4M | 19.9M | 17.2M | 16.9M | 16.6M | 16.1M | 15.2M | 14.7M | 14.1M | 12.7M | 9.2M | 4.5M | 4.2M | 3.9M | |
| Earnings Per Share Diluted | $-0.44 | $-0.30 | $-0.27 | $-0.24 | $-0.26 | $-0.25 | $-0.37 | $-0.38 | $-0.27 | $-0.42 | $-0.28 | $-0.32 | $-1.04 | $-1.43 | $0.01 | |
| Earnings Per Share Basic | $-0.44 | $-0.30 | $-0.27 | $-0.24 | $-0.26 | $-0.25 | $-0.37 | $-0.38 | $-0.27 | $-0.42 | $-0.28 | $-0.32 | $-1.04 | $-1.43 | $0.01 | |
| Common Stock Shares Authorized | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Common Stock Shares Issued | 25.6M | 23.9M | 23.6M | 19.0M | 18.7M | 18.4M | 17.3M | 17.2M | 15.9M | 14.6M | 12.7M | 12.7M | ||||
| Common Stock Shares Outstanding | 25.6M | 23.9M | 23.6M | 19.0M | 18.7M | 18.4M | 17.3M | 17.2M | 14.6M | 12.7M | 12.7M | |||||
| Temporary Equity Shares Authorized | 6.6M | |||||||||||||||
| Temporary Equity Shares Outstanding |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Finance Income | $1.1M | $847.0K | $637.0K | $149.0K | $4.0K |
| Additional Paid In Capital | $118.1M | $83.0M | $66.4M | $46.2M | $1.9M |
| Stock Issued During Period Value New Issues | $11.7M | $5.1M | $13.1M | ||
| Stock Issued During Period Value Warrants Exercised | $1.5M | ||||
| Offering Costs | $382.0K | $174.0K | |||
| Stock Issued During Period Value Stock Options Exercised | $38.0K | ||||
| Offering Cost On Exercise Of Preferred Investment Options | $755.0K | ||||
| Effect Of Warrant Modification | $2.4M | ||||
| Unpaid Issuance Costs Related To Offering | |||||
| Prefunded Warrants Issued During Period Value | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finance Income | $332.0K | $261.0K | $236.0K | $206.0K | $215.0K | $225.0K | $277.0K | $64.0K | $52.0K | $61.0K | $4.0K | $2.0K |
| Additional Paid In Capital | $116.4M | $101.8M | $99.5M | $78.0M | $75.4M | $72.4M | $64.3M | $62.1M | $48.3M | $45.7M | $30.9M | $30.4M |
| Stock Issued During Period Value New Issues | $521.0K | $1.5M | $1.7M | $4.7M | $1.1M | $3.1M | $13.1M | |||||
| Stock Issued During Period Value Warrants Exercised | $816.0K | $663.0K | ||||||||||
| Offering Costs | $49.0K | $55.0K | $153.0K | $39.0K | $152.0K | $1.7M | $2.9M | |||||
| Stock Issued During Period Value Stock Options Exercised | $38.0K | |||||||||||
| Offering Cost On Exercise Of Preferred Investment Options | $770.0K | |||||||||||
| Effect Of Warrant Modification | $2.4M | |||||||||||
| Unpaid Issuance Costs Related To Offering | $300.0K | |||||||||||
| Prefunded Warrants Issued During Period Value |
Most recent annual filing with the SEC: February 11, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.